Divi’s Laboratories Q4 FY26 Results: Strong Profit Growth and ₹30 Dividend Boost
Divi’s Laboratories reported a solid set of Q4 FY26 earnings, driven by steady demand in its pharmaceutical APIs and custom synthesis business. The company posted a 13% year-on-year rise in consolidated profit after tax (PAT) to ₹751 crore, compared to ₹662 crore in Q4 FY25. Revenue from operations also climbed nearly 10% YoY to ₹2,831 crore.
Along with the quarterly results, the pharma major announced a final dividend of ₹30 per equity share for FY26, subject to shareholder approval at the upcoming AGM.
Key Highlights of Divi’s Laboratories Q4 FY26 Results
| Metric | Q4 FY26 | Q4 FY25 | YoY Growth |
|---|---|---|---|
| Revenue from Operations | ₹2,831 crore | ₹2,585 crore | 9.5% |
| PAT | ₹751 crore | ₹662 crore | 13.4% |
| EBITDA | ₹934 crore | ₹886 crore | 5.4% |
| EBITDA Margin | 33% | 34.3% | Declined |
| Profit Before Tax | ₹963 crore | ₹864 crore | 11.5% |
The company also reported a strong forex gain during the quarter, which supported overall profitability.
Dividend Announcement
Divi’s Laboratories recommended a final dividend of ₹30 per equity share with a face value of ₹2 each. This translates to a 1500% dividend payout for FY26.
Important Dividend Dates
- Record Date: July 24, 2026
- AGM Date: August 10, 2026
- Dividend payment will be made after shareholder approval at the AGM.
Full-Year FY26 Performance
For the full financial year FY26, Divi’s Laboratories delivered healthy growth across key financial metrics.
FY26 Financial Snapshot
| Metric | FY26 | FY25 | Growth |
|---|---|---|---|
| Revenue | ₹10,560 crore+ | ₹9,300 crore+ | 13% |
| PAT | ₹2,568 crore | ₹2,209 crore | 17% |
| EBITDA | ₹3,948 crore | NA | Strong Growth |
The company benefited from:
- Strong export demand
- Growth in custom synthesis business
- Stable operational execution
- Improved forex gains
EBITDA Margin Slightly Under Pressure
Although revenue and profit improved, EBITDA margins slipped to 33% from 34.3% last year. The moderation was mainly linked to operational costs and business mix changes during the quarter.
Despite the margin pressure, Divi’s Laboratories maintained strong profitability levels compared to peers in the pharmaceutical manufacturing sector.
Market Reaction and Share Price Outlook
Investors reacted positively to the earnings announcement and dividend declaration. Analysts continue to remain optimistic on Divi’s Laboratories due to:
- Strong balance sheet
- Consistent cash generation
- Leadership in API manufacturing
- Long-term CRDMO growth opportunities
Several brokerages expect the company to maintain healthy earnings momentum in FY27, especially if global pharmaceutical demand remains stable.
What’s Driving Divi’s Laboratories Growth?
Divi’s Laboratories continues to benefit from:
- Increasing demand for generic APIs
- Expansion in custom synthesis projects
- Strong global customer relationships
- Manufacturing scale advantages
The company’s focus on operational efficiency and export-driven growth has helped it remain one of India’s strongest pharma manufacturing companies.
Conclusion
Divi’s Laboratories delivered another steady quarter with double-digit profit growth and healthy revenue expansion. The company’s Q4 FY26 PAT of ₹751 crore, combined with a generous ₹30 final dividend, reflects management confidence and strong financial health.
While EBITDA margins saw a slight dip, Divi’s Laboratories remains well-positioned for long-term growth in the global pharmaceutical and API market.
FAQs
Q. What was Divi’s Laboratories Q4 FY26 PAT?
Divi’s Laboratories reported a consolidated PAT of ₹751 crore in Q4 FY26, up 13% YoY.
Q. How much dividend did Divi’s Laboratories announce?
The company announced a final dividend of ₹30 per equity share for FY26.
Q. What was Divi’s Laboratories Q4 FY26 revenue?
Revenue from operations stood at ₹2,831 crore during the quarter.
Q. What is the dividend record date?
The dividend record date is July 24, 2026.
Disclaimer
The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.
